Here's why Sun Pharma share price advanced 5% in trade on April 11; details

Q: How long will it take to read this news story?

The story "Here&#039;s why Sun Pharma share price advanced 5% in trade on April 11; details" has 452 words across 18 sentences, which will take approximately 2 - 4 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Here&#039;s why Sun Pharma share price advanced 5% in trade on April 11; details" was covered 2 weeks ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 105 news stories per day. It's most recent story was published 3 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #27782974</li><li>URL: https://apeiron.beamstart.com/news/heres-why-sun-pharma-share-17443457829609</li></ul>

Business Standard Logo Business Standard 2w ago

Here's why Sun Pharma share price advanced 5% in trade on April 11; details - Business Standard

Quick Summary:

The rise in the Sun Pharma share price came after a favourable ruling from a US court regarding its planned launch of Leqselvi (deuruxolitinib).

Founded in 1983, Sun Pharmaceutical Industries is the world’s fourth-largest specialty generic pharmaceutical company, with global revenues of $5.8 billion.

The company is ranked among the top generic pharmaceutical firms in the US, especially in the dermatology space, and maintains a strong presence across key emerging markets like Brazil, Mexico, Russia, and South Africa.